Valacyclovir for episodic treatment of genital herpes: A shorter 3-day treatment course compared with 5-day treatment

被引:52
作者
Leone, PA
Trottier, S
Miller, JM
机构
[1] Univ N Carolina, Dept Infect Dis, Div Infect Dis, Chapel Hill, NC 27599 USA
[2] GlaxoSmithKline, Res Triangle Pk, NC USA
[3] Univ Laval, Ctr Rech Infectiol, St Foy, PQ G1K 7P4, Canada
关键词
D O I
10.1086/339326
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Valacyclovir given in a 5-day regimen of 500 mg twice per day is effective as short-term treatment of episodes of recurrent genital herpes. This study compared the efficacy of a shorter, 3-day course (for 402 patients) with that of a 5-day course (for 398 patients) of valacyclovir for persons with frequent recurrence of symptoms. No significant differences were detected between the 2 dosing schedules for any of the end points measured. Median times to lesion healing, of pain duration, and of episode length for the 5-day versus 3-day treatment were 4.7 versus 4.4 days, 2.5 days versus 2.9 days, and 4.4 days versus 4.3 days, respectively. The proportions of patients with aborted lesions were 26.6% and 25.4% in the 5-day and 3-day groups, respectively. A 3-day course of 500 mg of valacyclovir administered twice daily as episodic treatment of recurrent genital herpes is equivalent to a 5-day course with regard to key markers of efficacy.
引用
收藏
页码:958 / 962
页数:5
相关论文
共 8 条
[1]   RECURRENCE RATES IN GENITAL HERPES AFTER SYMPTOMATIC FIRST-EPISODE INFECTION [J].
BENEDETTI, J ;
COREY, L ;
ASHLEY, R .
ANNALS OF INTERNAL MEDICINE, 1994, 121 (11) :847-854
[2]  
Bodsworth NJ, 1997, GENITOURIN MED, V73, P110
[3]   Herpes simplex virus type 2 in the United States, 1976 TO 1994 [J].
Fleming, DT ;
McQuillan, GM ;
Johnson, RE ;
Nahmias, AJ ;
Aral, SO ;
Lee, FK ;
StLouis, ME .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (16) :1105-1111
[4]  
Marques A R, 2000, Adv Intern Med, V45, P175
[5]   Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection [J].
Patel, R ;
Tyring, S ;
Strand, A ;
Price, MJ ;
Grant, DM .
SEXUALLY TRANSMITTED INFECTIONS, 1999, 75 (06) :398-402
[6]  
PATEL R, 2000, STIS MILL PAST PRESE, P15
[7]   A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis [J].
Spruance, SL ;
Tyring, SK ;
DeGregorio, B ;
Miller, C ;
Beutner, K ;
Alsever, J ;
DAndreSmith, V ;
Appel, T ;
Beauford, W ;
Bernstein, DI ;
Brooks, J ;
Cameron, W ;
Wald, A ;
DavidBajar, KM ;
Davis, R ;
Faro, S ;
Fife, K ;
Fisher, GB ;
Friedman, D ;
Goldberg, L ;
Gordon, S ;
Gratkins, L ;
Hanson, M ;
Havlichek, D ;
Hino, P ;
Kaufman, RH ;
Kurtz, T ;
Lang, W ;
Lappin, M ;
Lebwohl, M ;
Levin, ML ;
Levin, M ;
Mertz, GJ ;
Reitano, MV ;
Reza, L ;
Roth, R ;
Rudolph, T ;
Safrin, S ;
Stephens, S ;
Tipton, N ;
Trupin, S ;
VanAmerongen, D ;
Wanek, E ;
Whiting, D ;
Wright, B ;
Yockey, C ;
Zellner, SR ;
Delehanty, JT ;
Dix, L ;
Chulay, JD .
ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (15) :1729-1735
[8]   A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections [J].
Tyring, SK ;
Douglas, JM ;
Corey, L ;
Spruance, SL ;
Esmann, J .
ARCHIVES OF DERMATOLOGY, 1998, 134 (02) :185-191